

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

Review of NICE Technology Appraisal Guidance No.158; Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza, and No.168; Amantadine, oseltamivir and zanamivir for the treatment of influenza

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Alliance Pharmaceuticals (amantadine) • GlaxoSmithKline UK (zanamivir) • Roche Products (oseltamivir) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Against Allergy • Action for Sick Children • Afiya Trust • African Health Policy Network • Allergy UK • Asthma UK • AVERT • Black and Ethnic Minority Diabetes Association • Black Health Agency • Brain and Spine Foundation • British Cardiac Patients Association • British Kidney Patient Association • British Liver Trust • British Lung Foundation • Cardiovascular Care Partnership • Children's Liver Disease Foundation • Children's Society • Diabetes Research and Wellness Foundation • Diabetes UK • Equalities National Council • Heart UK • Juvenile Diabetes Research Foundation • Muslim Council of Britain • Muslim Health Network • NAM Publications • National AIDs Trust 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Diabetes UK Cymru • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Kidney Patients Association <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Alliance Pharmaceuticals (amantadine) • GlaxoSmithKline UK (zanamivir) • Roche Products (oseltamivir) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Acute Respiratory Infections Group • Cochrane Heart Group • Cochrane Metabolic & Endocrine Disorders Group • Cochrane Renal Group • Health Research Authority

<ul style="list-style-type: none"> • National Children’s Bureau • National Kidney Federation • National Parent Partnership Network • Network of Sikh Organisations • Neurological Alliance • Neurosupport • South Asian Health Foundation • Specialised Healthcare Alliance • Surya Foundation • Terrence Higgins Trust • WellChild <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Clinical Diabetologists • Association of Renal Technologists • Association of Respiratory Nurse Specialists • British Association for Nursing in Cardiovascular Care • British Association for Paediatric Nephrology • British Association for the Study of the Liver (BASL) • British Association for the Study of the Liver Nurses Forum (BASLNF) • British Cardiovascular Intervention Society • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British HIV Association • British Liver Nurses Forum • British Paediatric Respiratory Society • British Renal Society • British Society for Paediatric Endocrinology & Diabetes • British Thoracic Society • Diabetes Specialist Nurses • Faculty of Public Health Medicine • Primary Care Cardiovascular Society • Primary Care Diabetes Society • Primary Care Respiratory Society UK • Renal Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health 	<ul style="list-style-type: none"> • Institute for Ageing and Health • MRC Clinical Trials Unit • National Heart Research Fund • National Institute for Health Research • Research Institute for the Care of Older People <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Evidence Review Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales NHS Trust
---	--

<ul style="list-style-type: none"> • Royal College of Pathologists • Royal College of Physicians • Royal Institute of Public Health and Hygiene • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists • UK Health Forum • UK Renal Pharmacy Group • United Kingdom Clinical Pharmacy Association • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Leeds South and East CCG • NHS Telford & Wrekin CCG • Welsh Government 	
--	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.